AVIR
AteaCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
AVIR vs peer average
53/100
AVIR vs. peer average (C vs. C)
Grade spread
A 2 · B 2 · D 4 · F 2
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
GILD is the first available peer comparator.
Direct HCV operating comparator rather than a same-market-cap peer: Atea uses sofosbuvir/velpatasvir, marketed as Epclusa by Gilead, as the active comparator in C-BEYOND, so GILD is the clearest benchmark for efficacy, safety, and commercial bar setting [#10-K-2026-03-05].
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
AVIR
Atea
GILD
Gilead Sciences
Grade
C
B
Momentum
76
64
Value
41
66
Sentiment
59
60
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Constructive
Grade position vs GILD
AVIR / GILD
Grade Position
In line
AVIR vs. peer average (C vs. C)
53/100
Momentum
76
AVIRValue
41
GILDSentiment
59
GILDRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs AVIR
GILD is the first peer returned for this comparison set.